EMBECTA CORP. Increase (Decrease) in Accounts Receivable
EMBECTA CORP. (EMBC) reported Increase (Decrease) in Accounts Receivable of $20.80 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-07
- EMBECTA CORP. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $20.10M.
- EMBECTA CORP. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$11.30M, a 638.10% decline year-over-year.
- EMBECTA CORP. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $12.00M.
- EMBECTA CORP. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$32.50M, a 275.68% decline year-over-year.
- EMBECTA CORP. increase (decrease) in accounts receivable for fiscal 2025 was -$44.20M, a 125.30% decline from fiscal 2024.
- EMBECTA CORP. increase (decrease) in accounts receivable for fiscal 2024 was $174.70M.
- EMBECTA CORP. increase (decrease) in accounts receivable for fiscal 2023 was -$7.00M.
- EMBECTA CORP. increase (decrease) in accounts receivable for fiscal 2022 was -$122.70M, a 485.85% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | $8.80M derived: sum of 2 quarters · filed 2026-08-07 | $20.80M 10-Q · filed 2026-08-07 | -$11.70M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$11.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | $700.00K 10-Q · filed 2026-05-05 | -$31.80M derived: sum of 3 quarters · filed 2026-05-05 | -$39.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $12.00M 10-Q · filed 2026-02-05 | -$20.50M derived: sum of 2 quarters · filed 2026-02-05 | -$28.50M derived: sum of 3 quarters · filed 2026-08-07 | -$26.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | -$32.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$40.50M derived: sum of 2 quarters · filed 2026-08-07 | -$38.40M derived: sum of 3 quarters · filed 2026-08-07 | -$44.20M 10-K · filed 2025-11-25 |
| 2025-06-30 | -$8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | -$5.90M derived: sum of 2 quarters · filed 2026-08-07 | -$11.70M 10-Q · filed 2026-08-07 | $6.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | -$3.70M 10-Q · filed 2026-05-05 | $14.80M derived: sum of 3 quarters · filed 2026-05-05 | $64.30M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$5.80M 10-Q · filed 2026-02-05 | $12.70M derived: sum of 2 quarters · filed 2026-02-05 | $62.20M derived: sum of 3 quarters · filed 2026-02-05 | $90.30M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $18.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $68.00M derived: sum of 2 quarters · filed 2025-11-25 | $96.10M derived: sum of 3 quarters · filed 2025-11-25 | $174.70M 10-K · filed 2025-11-25 |
| 2024-06-30 | $49.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-08 | $77.60M derived: sum of 2 quarters · filed 2025-08-08 | $156.20M 10-Q · filed 2025-08-08 | $152.30M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $28.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-09 | $106.70M 10-Q · filed 2025-05-09 | $102.80M derived: sum of 3 quarters · filed 2025-11-25 | $104.00M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $78.60M 10-Q · filed 2025-02-06 | $74.70M derived: sum of 2 quarters · filed 2025-11-25 | $75.90M derived: sum of 3 quarters · filed 2025-11-25 | $74.60M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | -$3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$2.70M derived: sum of 2 quarters · filed 2025-11-25 | -$4.00M derived: sum of 3 quarters · filed 2025-11-25 | -$7.00M 10-K · filed 2025-11-25 |
| 2023-06-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | -$100.00K derived: sum of 2 quarters · filed 2024-08-09 | -$3.10M 10-Q · filed 2024-08-09 | -$2.20M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | -$1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | -$4.30M 10-Q · filed 2024-05-09 | -$3.40M derived: sum of 3 quarters · filed 2024-12-11 | $6.30M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | -$3.00M 10-Q · filed 2024-02-09 | -$2.10M derived: sum of 2 quarters · filed 2024-12-11 | $7.60M derived: sum of 3 quarters · filed 2024-12-11 | -$95.00M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $10.60M derived: sum of 2 quarters · filed 2024-12-11 | -$92.00M derived: sum of 3 quarters · filed 2024-12-11 | -$122.70M 10-K · filed 2024-12-11 |
| 2022-06-30 | $9.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | -$92.90M derived: sum of 2 quarters · filed 2023-08-08 | -$123.60M 10-Q · filed 2023-08-08 | -$93.40M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | -$102.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | -$133.30M 10-Q · filed 2023-05-12 | -$103.10M derived: sum of 3 quarters · filed 2023-11-29 | |
| 2021-12-31 | -$30.70M 10-Q · filed 2023-02-14 | -$500.00K derived: sum of 2 quarters · filed 2023-11-29 | ||
| 2021-09-30 | $30.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $31.80M 10-K · filed 2023-11-29 | ||
| 2021-06-30 | $1.60M 10-Q · filed 2022-08-15 | |||
| 2020-09-30 | $2.40M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |